Using entecavir to prevent hepatitis B flare-up in gastrointestinal cancer patients
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving the antiviral drug entecavir before or at the first sign of hepatitis B reactivation can prevent liver problems in gastrointestinal cancer patients who are inactive hepatitis B carriers and are starting chemotherapy or immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a gastrointestinal cancer (such as colorectal, stomach, esophageal, liver, pancreatic, or bile duct cancer) that cannot be removed by surgery or has spread.
- You are about to start your first, second, or third round of chemotherapy or immunotherapy (PD-1/PD-L1 drugs).
- You are physically active enough to handle daily activities (ECOG score 0-2).
- You have had hepatitis B in the past or are a chronic carrier, but the virus is currently inactive (negative HBV-DNA test).
- Your liver function and major organ function are within normal range.
- You have not had liver cirrhosis or a prior hepatitis B flare-up, and you are not on hepatitis B treatment now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares three hepatitis B (HBV) medicines to see which treatment helps people with a severe liver flare. You may be eligible if you have confirmed HBV and lab results showing significant liver stress.
This trial tests switching from standard entecavir pills to a different form (ODT, which dissolves in your mouth) for people who have had a stable liver transplant for hepatitis B. It aims to see if the new form works just as well and is safe.
This trial tests if taking tenofovir alafenamide (TAF) alone works as well as combining it with entecavir (ETV) to improve outcomes for people with hepatitis B and liver cancer who are receiving immunotherapy.
This trial tests whether adding a short course of interferon to standard antiviral medicine (entecavir) helps younger children with chronic hepatitis B whose immune system has not yet started fighting the virus. It aims to see if this combination can lead to a functional cure.
This study tracks chronic hepatitis B patients who have a family history of liver cancer to understand their risk. It tests how well current antiviral treatments work in this group.
This trial tests whether taking the antiviral medicine entecavir before and after a stem cell transplant can prevent hepatitis B from “waking up” again. It may help protect your liver during a high-risk treatment period.
Hear when a new Gastrointestinal Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.